Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales.
May 20, 2015
0
4
Dying patients sometimes seek emergency access to experimental medicines, desperate for a last-chance treatment even if there's little proof it could help. Now drug giant Johnson & Johnson is taking an unusual step, turning ...
May 7, 2015
0
8
US health care giant Johnson & Johnson announced plans Friday to collaborate with Google on surgical robotics.
Mar 27, 2015
0
8
Amgen Inc., the Thousand Oaks, Calif., biotech giant, said Sunday a new study has found its cancer drug Kyprolis is far more effective in treatment of relapsed multiple myeloma than its chief rival.
Mar 3, 2015
0
6
Boston Scientific will pay $600 million to settle with drugmaker Johnson & Johnson over the medical device maker's $27 billion acquisition of Guidant Corp. in 2006.
Feb 17, 2015
0
4
Imagine being able to identify people likely to develop a particular disease—and then stop it before it starts. This isn't a science fiction tale. It's the ambitious goal of three research projects just launched by Johnson ...
Feb 12, 2015
0
12
There is no licensed vaccine or treatment for Ebola, which has killed more than 8,600 people in West Africa out of more than 21,700 infected since the start of 2014.
Jan 23, 2015
0
4
The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data sharing is made ...
Jan 14, 2015
0
3
The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access to groundbreaking ...
Dec 22, 2014
0
1
U.S. regulators on Monday strengthened their warning against use of a once-popular device for gynecologic surgery that can spread unsuspected cancer, saying its risk is only justified in a fraction of patients.
Nov 24, 2014
0
0
